Blood test may lead to targeted therapy for prostate cancer

Conclusion Genetic testing is becoming more common in cancer treatment as a way of tailoring treatment to the individual cancer. It's already used in breast cancer, for example. This test could help identify which men that have not responded to hormone treatment are most likely to benefit from two of the newer prostate cancer drugs. It is good news, because men could then be spared treatment that is unlikely to help them, and directed towards more suitable treatment options. Also, both of these newer drugs are very expensive, so a suitable test could save the NHS a great deal of money. Meanwhile, those men who are likely to benefit will take the drug knowing it's likely to help. However, we're some way off being able to use the test in practice. This research shows that, among a group of 265 men, those with multiple copies of the androgen receptor gene did worse after treatment than those without. That doesn't prove that selecting patients for treatment based on AR gene status will improve outcomes. We need to see studies that select patients for treatment based on their test results, and follow them up to see how they do, to be sure the test is truly helpful. Links To The Headlines Prostate cancer: Blood test could help target treatment. BBC News, May 4 2017 Blood test could help prostate cancer treatment. ITV News, May 4 2017 £50 blood test boosts chances of surviving prostate cancer. The Times, May 4 2017 (subscription required) Links To Science Conteduc...
Source: NHS News Feed - Category: Consumer Health News Tags: Cancer Medication Source Type: news

Related Links:

MicroRNAs (miRNAs) are a class of single-stranded RNAs, 18-23 nucleotides in length that regulate gene expression at the post-transcriptional level. Dysregulation of miRNAs has been closely associated with the development of cancer. In the process of tumorigenesis, mammalian target of rapamycin (mTOR) plays important roles, and the mTOR signaling pathway is aberrant in various types of human cancers, including non-small cell lung cancer (NSCLC), breast cancer, prostate cancer, as well as others. However, the relationship between miRNAs and the mTOR signaling pathway is indistinct. Herein, we not only summarize the progress...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Lung cancer is the leading cause of cancer death after prostate cancer for males and breast cancer for females. There are novel therapies in the past five years such as; tyrosine kinase inhibitors and most recently in the last two years immunotherapy. Immunotherapy is currently being investigated if it can be administered alone or in combination. Previously we have investigated whether immunotherapy compounds can be produced as aerosols, and in the current study we investigated the safety and efficiency independently of the programmed death-ligand 1. The aerosol administration of both cisplatin and nivolumab is possible. T...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Conclusions We report an increased risk of EPMs in patients with IPMN, especially for renal cell, prostate, colorectal, and breast cancer.
Source: Pancreas - Category: Gastroenterology Tags: Original Articles Source Type: research
Authors: Kim GJ, Jo HJ, Lee KJ, Choi JW, An JH Abstract We evaluated oleanolic acid (OA)-induced anti-cancer activity, apoptotic mechanism, cell cycle status, and MAPK kinase signaling in DU145 (prostate cancer), MCF-7 (breast cancer), U87 (human glioblastoma), normal murine liver cell (BNL CL.2) and human foreskin fibroblast cell lines (Hs 68). The IC50 values for OA-induced cytotoxicity were 112.57 in DU145, 132.29 in MCF-7, and 163.60 in U87 cells, respectively. OA did not exhibit toxicity in BNL CL. 2 and Hs 68 cell lines in our experiments. OA, at 100 µg/mL, increased the number of apoptotic cells to 27....
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Draft guidance dubs Perjeta ‘not cost effective’ Related items fromOnMedica NICE fast-tracks approval of new skin cancer treatment New breast cancer drug ‘unaffordable’ for NHS One in 10 children in phase I cancer trials respond to drugs Cancer strategies failed to improve one-year survival Genetic risk model could guide prostate cancer screening
Source: OnMedica Latest News - Category: UK Health Source Type: news
Henrik Franzyk Since cells in solid tumors divide less rapidly than cells in the bone marrow or cells of the immune system, mitotic inhibitors often cause severe side effects when used for treatment of diseases like prostate cancer and breast cancer. One approach to overcome this problem involves attempts at developing drugs based on general cytotoxins, like calicheamicin and thapsigargin, which kill cells at all phases of the cell cycle. However, such toxins can only be used when efficient targeting to the malignant tissue is possible. In the case of thapsigargin, selectivity for tumor-associated cells is achieved b...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
AbstractPurposeSuperparamagnetic nanoparticles of iron oxide (SPION) were shown to be non-inferior to standard radioisotope tracer in breast cancer and may be used as an alternative to identify sentinel lymph nodes (SLN). The aim of this study was to assess the feasibility of sentinel lymph node dissection (SLND) using SPION in prostate cancer and to evaluate its diagnostic accuracy.MethodsTwenty patients with intermediate- and high-risk prostate cancer were prospectively enrolled in 2016. After intraprostatic injection of SPION, SLND using magnetometer was performed the following day. Extended pelvic lymph node dissection...
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
BJU International, EarlyView.
Source: BJU International - Category: Urology & Nephrology Authors: Source Type: research
We describe the syntheses of nine new angucyclinone 6-aza-analogues, achieved through a hetero Diels-Alder reaction between the shikimic acid derivative-azadiene 13, with different naphthoquinones. The cytotoxic activity of the new synthesized compounds and five angucyclinones, previously reported, was evaluated in vitro against three cancer cell lines: PC-3 (prostate cancer), HT-29 (colon cancer), MCF-7 (breast cancer), and one non-tumoral cell line, human colon epithelial cells (CCD841 CoN). Our results showed that most 6-azadiene derivatives exhibited significant cytotoxic activities, which was demonstrated by their IC5...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
Authors: Figueroa CD, Molina L, Bhoola KD, Ehrenfeld P Abstract The kallikrein family comprises tissue kallikrein and 14 kallikrein-related peptidases (KLKs) recognized as a subgroup of secreted trypsin- or chymotrypsin-like serine proteases. KLKs are expressed in many cellular types where they regulate important physiological activities such as semen liquefaction, immune response, neural development, blood pressure, skin desquamation and tooth enamel formation. Tissue kallikrein, the oldest member and kininreleasing enzyme, and KLK3/PSA, a tumor biomarker for prostate cancer are the most prominent components of th...
Source: Biological Chemistry - Category: Chemistry Tags: Biol Chem Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | CT Scan | Docetaxel | Genetics | Health | Hormones | Men | PET Scan | Prostate Cancer | Science | Study | Taxotere | Universities